title: [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
abstract: A 73-year-old man diagnosed as having pancreatic body cancer with multiple liver metastases was referred to our hospital. Since the patient preferred oral agents, S-1 monotherapy (4-week administration followed by 2-week interval) was started. The initial dose of S-1 was 80 mg, and gradually increased to 150 mg/day. There were no significant adverse events. The liver metastases disappeared and the pancreatic tumor was markedly reduced in size at the completion of 4 courses. Distal pancreatectomy was carried out at 7 months since his first visit. Pathological diagnosis was non-functioning well-differentiated neuroendocrine carcinoma (pT4, pN0, pM0, Stage IVa). He is alive without relapse 6 months after operation. S-1 might be a candidate for chemotherapy for this neuroendocrine tumor.
authors.affiliation: Department of Medical Oncology, Kanazawa Medical University.
authors.forename: Itaru
authors.initials: I
authors.lastname: Sato
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Ueda
authors.forename: Eriko
authors.initials: E
authors.lastname: Kinoshita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Minato
authors.forename: Kenji
authors.initials: K
authors.lastname: Ohno
authors.forename: Naoki
authors.initials: N
authors.lastname: Nakaya
authors.forename: Takeo
authors.initials: T
authors.lastname: Shimasaki
authors.forename: Hideo
authors.initials: H
authors.lastname: Nakajima
authors.forename: Takeo
authors.initials: T
authors.lastname: Kosaka
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Motoo
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D010094:Oxonic Acid / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D049268:Positron-Emission Tomography; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid